# Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)

> **NCT00395603** · PHASE3 · TERMINATED · sponsor: **Organon and Co** · enrollment: 550 (estimated)

## Conditions studied

- Cardiovascular Diseases
- Diabetes Mellitus

## Interventions

- **DRUG:** MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks
- **DRUG:** Comparator: atorvastatin / Duration of Treatment: 6 Weeks

## Key facts

- **NCT ID:** NCT00395603
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-09
- **Primary completion:** 2007-06
- **Final completion:** 2007-06
- **Target enrollment:** 550 (ESTIMATED)
- **Why stopped:** This study was terminated early due to poor recruitment.
- **Last updated:** 2024-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00395603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00395603, "Vytorin Treating Uncontrolled Lipids (VyTUL) Study (0653A-122)". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00395603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*